Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obrixtamig plus ZL-1310 in advanced small cell lung cancer and other poorly differentiated neuroendocrine carcinomas
2026-525634-27-00Phase 2Authorised
- Sponsor
- Boehringer Ingelheim
- Start
- Nov 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 11
01
Overview
Phase 2, open-label trial of obrixtamig and zocilurtatug pelitecan in small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC) and extrapulmonary neuroendocrine carcinoma (EPNEC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events leading to discontinuation or dose modification and 1 more. Planned start Nov 2026; status: authorised.
02
Drugs
obrixtamigzocilurtatug pelitecan
03
Conditions
small cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)extrapulmonary neuroendocrine carcinoma (EPNEC)
Beyond the preview
Go deeper on 2026-525634-27-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-525634-27-00.